Jabs for 5-to-11-year-olds — Pfizer-BioNTech to seek approval by 'mid-October'
BioNTech's co-founders have said that an application to vaccinate 5-to-11-year-olds will be submitted to health agencies around the world "in the coming weeks" — and that the data from those trials "looks good." In the same interview with Der Spiegel, the CEO of BioNTech said Germany has "60 days to avoid a harsh winter."